Text Size

Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors

This study has been completed.
Sponsor:
Information provided by:
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT00003882
First received: November 1, 1999
Last updated: March 3, 2011
Last verified: March 2011
History of Changes
  Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of anhydrovinblastine in treating patients who have advanced recurrent solid tumors.


Condition Intervention Phase
Unspecified Adult Solid Tumor, Protocol Specific
 Drug: anhydrovinblastine
 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Dose Finding Study of Anhydrovinblastine Administered as a 1-Hour Infusion Every 3 Weeks to Patients With Advanced Solid Tumors

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by Roswell Park Cancer Institute:

Enrollment: 10
Study Start Date: March 1999
Study Completion Date: September 2000
Primary Completion Date: April 2000 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES: I. Determine the maximum tolerated dose and assess the toxicity of anhydrovinblastine in patients with advanced refractory solid tumors. II. Assess the safety, pharmacokinetics, and efficacy of this treatment regimen in this patient population.

OUTLINE: This is a dose escalation study. Patients receive anhydrovinblastine IV over 1 hour on day 1. Courses are repeated every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. The dose of anhydrovinblastine is escalated in cohorts of 1-6 patients until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose that at which no more than 2 of 6 patients experience dose limiting toxicity. Patients are followed at 1 month after treatment, and then monthly until death.

PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study within 8 months.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS: Histologically confirmed advanced solid tumor unresponsive to existing therapy and for which no curative therapy exists No hematologic malignancies

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 12 weeks Hematopoietic: Absolute neutrophil count at least 1500/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL Hepatic: SGOT and SGPT no greater than 2.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 2.5 times ULN (except with bone metastases) PT and PTT no greater than ULN Bilirubin no greater than ULN Renal: Creatinine no greater than ULN OR Creatinine clearance at least 60 mL/min Cardiovascular: No congestive heart failure, angina pectoris (even if medically controlled), uncontrolled hypertension, arrhythmias, elevated CPK or recent EKG changes At least one year since myocardial infarction Neurologic: No history of neurologic or psychiatric disorders (e.g., dementia, seizures) No concurrent peripheral neuropathy greater than grade 1 Other: Not pregnant or nursing Fertile patients must use effective contraception No active infection No active pancreatitis Amylase no greater than the upper limit of normal No other serious systemic disease

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy and recovered No concurrent immunotherapy No concurrent colony stimulating factors (unless evidence of neutropenic infection) Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for nitrosourea or mitomycin) Prior taxanes and vinca alkaloids allowed with recovery (excluding alopecia any grade and peripheral neuropathy no greater than grade 1) No other concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior radiotherapy and recovered At least 6 weeks since prior extensive radiotherapy to greater than 20% of bone marrow No concurrent radiotherapy Surgery: Not specified Other: No other concurrent experimental drugs At least 30 days since other investigational drug

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00003882

Locations
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263-0001
Sponsors and Collaborators
Roswell Park Cancer Institute
Investigators
Study Chair: Nithya Ramnath, MD Roswell Park Cancer Institute
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

Publications:
Schwartz GN, Bong D, Leichman CG, et al.: Phase I evaluation of anhydrovinblastine in patients with advanced malignancies. [Abstract] Proc Am Assoc Cancer Res 41: 3895a, 2000.

Responsible Party: Nithya Ramnath, MD, Roswell Park Cancer Institute
ClinicalTrials.gov Identifier: NCT00003882     History of Changes
Other Study ID Numbers: CDR0000067049, RPCI-DS-9844
Study First Received: November 1, 1999
Last Updated: March 3, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Roswell Park Cancer Institute:
unspecified adult solid tumor, protocol specific

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on June 18, 2013